The company said in late January that the vaccine was 66 percent effective in a global study, with efficacy ranging as high as 72 percent in the U.S.
Johnson & Johnson seeks emergency authorization for vaccine
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться